---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-279803"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2026-06-23T21:28:13+00:00"
generated_at: "2026-06-23T21:30:24.733077+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Enanta loses Federal Circuit appeal; Paxlovid patent claims invalidated

## Summary
- Federal Circuit affirmed Dec 2024 summary judgment, ruling claims of U.S. Patent No. 11,358,953 invalid.
- Patent covered Pfizer's COVID-19 antiviral Paxlovid (nirmatrelvir; ritonavir).
- Enanta had sought damages for infringement; appeal loss eliminates potential royalty stream.
- Decision issued on June 23, 2026 by the U.S. Court of Appeals for the Federal Circuit.

## SEC filing metadata
- accession: 0001193125-26-279803
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2026-06-23T21:28:13+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000119312526279803/0001193125-26-279803-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000119312526279803/d133783d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-279803
- JSON: https://secwatch.observer/filing/0001193125-26-279803.json
- Plain text: https://secwatch.observer/filing/0001193125-26-279803.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.